💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

EU drugs agency faces gap at top awaiting new boss

Published 11/01/2010, 12:44 PM
Updated 11/01/2010, 12:48 PM

* European Medicines Agency head stepping down in December

* Appointment delays may mean no new leader until mid-2011

* Job finally re-advertised after earlier snags and pay row By Ben Hirschler

LONDON, Nov 1 (Reuters) - The European Medicines Agency could be leaderless for much of next year, after a series of missteps and a row over pay that stalled the appointment of a replacement for its outgoing executive director. A fresh advertisement for the post was finally published at the weekend, after multiple delays, but a new head of agency -- Europe's equivalent of the U.S. Food and Drug Administration -- is unlikely to be in place before mid-2011.

"There will be a gap," Thomas Lonngren, the outgoing executive director, told Reuters in a recent interview.

"Now I have only got a few months left and a procedure like this takes quite a long time, so we cannot expect (a replacement) until June or July next year."

The absence of a leader comes at a sensitive time for the London-based watchdog, which faces strategic choices about how it cooperates with other regulators around the world as the development of drugs becomes increasingly globalised.

But industry experts said the agency, which employs some 500 staff, is less subject to political pressures than its U.S. counterpart, suggesting the absence of an executive director may not disrupt day-to-day decisions on new drug approvals.

Divisional heads are expected to step into the breach to fill the role until a permanent replacement for Lonngren comes on board.

Lonngren, a Swedish pharmacist, has been the executive director of the agency since January 2001 and is currently serving a second five-year term, which expires at the end of 2010.

The European Commission, the Brussels-based bureaucracy responsible for selecting his successor, first advertised the post in January. But that posting had to be cancelled due to incorrect translations.

A second advertisement was then published, but was again pulled, following a row about the pay grade for the position, which the Commission planned to downgrade to AD14 from AD15 on the official European pay scale.

After much wrangling, the latest advertisement -- which appeared a few weeks later than Lonngren had expected -- maintains the executive director position at the existing grade of AD15.

That means the successful applicant will receive 176,000-199,000 euros ($246,000-$278,000) a year, rather than the 155,000-176,000 payable for grade AD14. ($1=0.7158 euros) (Editing by Greg Mahlich)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.